Begin main content

Call for Patient Input: Cinqair, Fasenra and Nucala

Published on: October 24, 2018
Result type: News

CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.

Cinqair

Brand name Generic name Manufacturer Indication(s)
Cinqair reslizumab TEVA Canada Innovation Asthma, eosinophilic
Project Number Call for patient input Patient input deadline Submit patient input
SF0591-000 2018-10-24 2018-12-12 Submit

Fasenra

Brand name Generic name Manufacturer Indication(s)
Fasenra benralizumab AstraZeneca Canada Inc. Asthma, severe eosinophilic
Project Number Call for patient input Patient input deadline Submit patient input
SF0592-000 2018-10-24 2018-12-12 Submit

Nucala

Brand name Generic name Manufacturer Indication(s)
Nucala mepolizumab GlaxoSmithKline Inc. Asthma, severe eosinophilic
Project Number Call for patient input Patient input deadline Submit patient input
SF0593-000 2018-10-24 2018-12-12 Submit